PSA — What It Measures and What It Does Not Tell You

---

PSA stands for prostate-specific antigen. It is a protein produced by the prostate gland — both normal prostate cells and prostate cancer cells — and its level in the blood is measured through a simple blood test.

A PSA level above 4.0 ng/mL is traditionally considered elevated. But this number is not a diagnosis. Elevated PSA is a signal that something may be wrong with the prostate — not proof that cancer is present.

PSA rises for several reasons other than cancer. Benign prostatic hyperplasia — a non-cancerous enlarged prostate — raises PSA. Prostatitis — infection or inflammation of the prostate — raises PSA dramatically and temporarily.

Even vigorous exercise or sexual activity in the 48 hours before a test can affect the reading.

Roughly 75 percent of men with a PSA between 4 and 10 ng/mL who go on to have a biopsy do not have prostate cancer.

This is why the PSA test alone is not sufficient to diagnose cancer and why additional investigations — starting with an MRI — are essential before any biopsy decision is made.

What PSA levels mean in practice

A PSA below 4 ng/mL is generally considered normal for most men, though the risk of prostate cancer is not zero even at these levels.

Approximately 15 percent of men with a PSA below 4 have prostate cancer found on biopsy, and a small proportion of these are clinically significant.

PSA between 4 and 10 ng/mL sits in what urologists call the grey zone. Cancer may or may not be present. This is the range where an MRI is most valuable in deciding whether a biopsy is truly necessary.

PSA above 10 ng/mL significantly increases the probability that cancer is present. A PSA of 50, 100, or higher — particularly with symptoms — is a strong indicator of significant disease and warrants urgent investigation.

PSA kinetics — velocity and doubling time

A single PSA reading is less informative than the trajectory over time. PSA velocity is how fast the number is rising per year. PSA doubling time is how long it takes the PSA to double.

A PSA rising by more than 0.75 ng/mL per year, or a doubling time of less than three years, indicates that something is growing — and that further investigation cannot wait.

If you have a series of PSA results over time, bring all of them to any oncology consultation. The trend is often more important than the most recent number.

Multiparametric MRI — Why It Comes Before the Biopsy

---

The multiparametric MRI — mpMRI — has become the most important diagnostic investigation in modern prostate cancer management.

It has changed the way prostate cancer is diagnosed and staged, and it is now the recommended first investigation when PSA is elevated or a cancer diagnosis is suspected.

An mpMRI uses multiple imaging sequences — T2-weighted, diffusion-weighted, and dynamic contrast-enhanced — to produce detailed images of the prostate and its surrounding tissue.

It can identify suspicious areas within the prostate, assess whether the tumour has broken through the prostate capsule, and evaluate nearby lymph nodes.

It is not a biopsy and it cannot confirm cancer on its own. But it can tell the reporting radiologist where to look — and, crucially, it can tell them whether a biopsy is even warranted.

The PI-RADS score — how mpMRI results are reported

The Prostate Imaging-Reporting and Data System — PI-RADS — is a standardised scoring system radiologists use to describe what they see on an mpMRI. Scores run from 1 to 5.

PI-RADS 1 means there is very low suspicion of clinically significant cancer — essentially a clean scan. PI-RADS 2 is low suspicion. PI-RADS 3 is equivocal — the scan neither confidently rules cancer in nor out.

PI-RADS 4 is high suspicion. PI-RADS 5 means the radiologist is highly suspicious that a clinically significant cancer is present.

Most guidelines now recommend that men with a PI-RADS 1 or 2 score — a negative or near-negative MRI — can safely defer biopsy and return for monitoring rather than proceeding immediately.

Men with PI-RADS 4 or 5 scores should proceed to biopsy. PI-RADS 3 is a grey zone that requires clinical judgement.

This is one of the most important developments in prostate cancer diagnosis in the past decade.

Before mpMRI became standard, many men had biopsies based on PSA alone — and a significant proportion of those biopsies were unnecessary. The MRI-first approach reduces unnecessary biopsies by approximately 28 percent.

mpMRI in India — availability and cost

A high-quality mpMRI of the prostate costs USD 200 to 350 at a major Indian cancer centre — compared to USD 1,500 to 3,000 in the United States. All nine hospitals in GAF Healthcare's prostate cancer network offer mpMRI with reporting by specialist uro-radiologists.

If you have had an mpMRI in your home country, bring the imaging disc as well as the written report. In most cases the Indian specialist will review the existing MRI rather than repeating it — provided it is a recent, high-quality scan on a 3 Tesla or above magnet.

Prostate Biopsy — TRUS vs Transperineal vs Fusion-Guided

---

A prostate biopsy is the only way to confirm that cancer is actually present.

Elevated PSA and a suspicious MRI are both indicators — but cancer is only diagnosed when a pathologist examines actual prostate tissue under a microscope and finds cancer cells.

There are three main ways to perform a prostate biopsy, and the approach taken significantly affects both the accuracy of the result and the risk of complications.

Transrectal ultrasound-guided biopsy (TRUS)

TRUS was the standard biopsy technique for decades. The urologist inserts an ultrasound probe into the rectum to image the prostate, then passes biopsy needles through the rectal wall to take tissue samples.

It is effective but carries a meaningful infection risk — approximately 1 to 3 percent of TRUS biopsies result in serious infection, including sepsis, because the needle passes through the bacteria-laden rectum.

In the era of rising antibiotic resistance, this risk has become a genuine clinical concern at specialist centres.

TRUS biopsy is still performed at many hospitals. For straightforward cases it remains acceptable. But at high-volume specialist centres in India — including Fortis FMRI and Medanta — the transperineal approach has increasingly become the preferred technique.

Transperineal biopsy

In transperineal biopsy, the needles are passed through the skin of the perineum — the area between the scrotum and anus — rather than through the rectum. This eliminates the infection risk from rectal bacteria entirely.

Serious infection rates after transperineal biopsy are below 0.5 percent — compared to 1 to 3 percent for TRUS. It also provides better access to the anterior and apical zones of the prostate, which TRUS can miss.

The transperineal approach requires general or spinal anaesthesia or deep sedation — but the safety improvement justifies this.

MRI-fusion targeted biopsy

MRI-fusion biopsy — also called cognitive fusion or software fusion — combines the mpMRI image with real-time ultrasound to guide needles precisely to the suspicious areas identified on the MRI.

Rather than taking systematic random samples across the prostate, fusion biopsy targets the specific areas flagged as suspicious.

This increases the detection rate for clinically significant cancer and reduces the detection of insignificant cancer that would not require treatment.

MRI-targeted biopsy is the current best-practice approach recommended by European and American urology guidelines for men with a PI-RADS 3, 4, or 5 lesion on mpMRI. It is available at all major Indian cancer centres that GAF Healthcare recommends.

What happens after the biopsy

The tissue samples are sent to a pathology laboratory where a histopathologist examines them under a microscope. Results typically take three to five working days in India.

The report will state whether cancer was found, in how many cores it was present, what percentage of each core was involved, and the Gleason score.

Understanding what the Gleason score means is the next step — and it is arguably the most important number in the entire diagnostic process.

Gleason Score and Grade Groups — What Your Pathology Report Means

---

The Gleason score is the number that most men with a prostate cancer diagnosis find most confusing — and most frightening. Understanding it clearly removes a significant amount of unnecessary fear.

The Gleason system grades how abnormal the cancer cells look under the microscope compared to normal prostate cells. The more abnormal they look — the further they have drifted from normal architecture — the higher the grade, and the more aggressive the cancer is likely to be.

Grades run from 1 to 5. Grade 1 looks almost like normal prostate tissue. Grade 5 looks nothing like it — the cells are highly disordered and aggressive. Grade 1 and 2 are so rarely reported now that effective Gleason scores run from 6 to 10.

How the Gleason score is calculated

The pathologist identifies the two most common cancer patterns in the biopsy — called the primary and secondary grades — and adds them together. If the most common pattern is grade 3 and the second most common is grade 4, the Gleason score is 3+4=7.

The order matters. A 3+4=7 and a 4+3=7 both add up to 7, but they carry different clinical implications.

In a 4+3 tumour, the dominant pattern is grade 4 — more aggressive. In a 3+4 tumour, grade 3 predominates. Despite having the same total, the 4+3 tumour is considered higher risk.

Grade Groups — a simpler system

Because the Gleason sum was confusing and compressed into a narrow range of 6 to 10, the International Society of Urological Pathology introduced Grade Groups — a cleaner five-tier system that maps directly to prognosis.

Grade Group	Gleason score	What it means	Risk
Grade Group 1	Gleason 6 (3+3)	Cells look close to normal. Grows very slowly.	Low
Grade Group 2	Gleason 7 (3+4)	Mostly low-grade with some moderate pattern.	Intermediate — favourable
Grade Group 3	Gleason 7 (4+3)	Mostly moderate-grade pattern. More concerning.	Intermediate — unfavourable
Grade Group 4	Gleason 8 (4+4, 3+5, 5+3)	High-grade. Needs active treatment.	High
Grade Group 5	Gleason 9–10 (4+5, 5+4, 5+5)	Most aggressive. Cells look very abnormal.	Very high

The most important thing to understand about Grade Group 1 — Gleason 3+3=6 — is that despite having a cancer diagnosis, many of these men will never need active treatment during their lifetime.

The cancer is so slow-growing that it will not cause harm before other causes of mortality intervene.

This is the scientific basis for active surveillance — a clinically endorsed strategy of monitoring rather than treating low-risk prostate cancer.

A man told he has Gleason 6 disease should not automatically assume he needs surgery or radiation. This decision deserves careful discussion with a specialist.

Staging — T Stage, N Stage, M Stage and What They Mean

---

Staging describes where the cancer is — how far it has spread beyond the prostate itself. The TNM staging system is the universal language of cancer staging. T describes the primary tumour, N describes lymph node involvement, and M describes distant metastasis.

T stage — the primary tumour

T1 — Cancer cannot be felt on digital rectal examination and was not visible on imaging. Usually found incidentally — for example, in TURP chips sent for pathology. T1c specifically means the cancer was found because of an elevated PSA leading to a biopsy.

T2 — Cancer is confined within the prostate gland. T2a means it involves less than half of one lobe. T2b means more than half of one lobe. T2c means both lobes are involved. All T2 disease is considered localised and potentially curable.

T3 — Cancer has grown beyond the prostate capsule. T3a means extracapsular extension — the tumour has breached the prostate wall. T3b means the cancer has grown into the seminal vesicles. This is locally advanced disease.

T4 — Cancer has grown into adjacent structures — the bladder neck, external sphincter, rectum, or pelvic wall. This is more advanced locally and typically requires combined modality treatment.

N stage — lymph node involvement

N0 means no cancer in the regional lymph nodes. N1 means cancer has spread to one or more regional lymph nodes. Lymph node involvement significantly changes the treatment strategy — it typically requires systemic treatment alongside any local therapy.

M stage — distant spread

M0 means no distant metastasis. M1 means distant metastasis is present. M1a is spread to non-regional lymph nodes. M1b is spread to bone — the most common site of distant spread in prostate cancer. M1c is spread to other organs — lungs, liver, or other viscera.

Knowing your T, N, and M stage before any treatment decision is made is essential. It is not possible to choose appropriately between surgery, radiation, hormone therapy, or a combination without complete staging information.

PSMA PET-CT — the Most Accurate Staging Scan Available in India

---

PSMA PET-CT — prostate-specific membrane antigen positron emission tomography — is the most significant advance in prostate cancer staging of the past decade. It has replaced the conventional CT and bone scan combination for staging at most major cancer centres in India.

PSMA is a protein expressed in very high amounts on the surface of prostate cancer cells.

A PSMA PET-CT works by injecting a radioactive tracer that binds specifically to PSMA. Prostate cancer cells — wherever they are in the body — light up on the scan because they attract the tracer.

This means PSMA PET-CT can detect lymph node metastases, bone metastases, and organ metastases with far greater sensitivity than a conventional CT or bone scan.

The proPSMA trial demonstrated that PSMA PET-CT had 27 percentage points higher accuracy than the CT-plus-bone-scan combination for detecting metastatic disease.

When is PSMA PET-CT used?

Primary staging in high-risk disease: for men with Gleason 8 to 10 (Grade Group 4 or 5) or PSA above 20, PSMA PET-CT is now the preferred staging investigation.

Biochemical recurrence after treatment: when PSA rises after prostatectomy or radiation, PSMA PET-CT can detect the source of recurrence at PSA levels as low as 0.2 ng/mL — far lower than any other imaging modality.

This is where it is most transformative, because it identifies where the cancer has returned and guides targeted salvage treatment.

PSMA PET-CT eligibility for Lutetium-177 therapy: before Lu-PSMA treatment can be given, a PSMA PET-CT must confirm that the patient's tumours express sufficient PSMA to be targeted by the treatment.

PSMA PET-CT availability and cost in India

PSMA PET-CT costs USD 500 to 900 at major Indian cancer centres. In the United States the same scan costs USD 3,000 to 6,000. In the United Kingdom it costs GBP 2,500 to 4,000.

Critically, PSMA PET-CT is widely available in India at all major cancer centres — Medanta, Apollo, Fortis FMRI, Tata Memorial, and others.

In contrast, availability in the United States and United Kingdom is still limited to specialist centres and in some cases requires insurance pre-authorisation or long waiting times.

For international patients who have not had a PSMA PET-CT but need one — whether for initial staging or for recurrence investigation — coming to India for the scan alone, before deciding on treatment, is a practical and affordable option.

Risk Groups — Low, Intermediate, High and What Each Means for Treatment

---

Once PSA, biopsy, and staging results are in hand, the oncology team places the patient into a risk group. This risk group is the primary driver of what treatment is recommended.

The most widely used risk stratification system is the Cambridge Prognostic Group, which incorporates PSA level, Gleason Grade Group, and clinical T stage to place patients into five prognostic groups.

A simpler three-tier system — low, intermediate, high — is also widely used clinically and is the basis for the following descriptions.

Low risk — what it means and what it does not

Low-risk prostate cancer is typically defined as Gleason Grade Group 1 (Gleason 6), PSA below 10, and clinical stage T1 or T2a, with cancer in fewer than 50 percent of biopsy cores.

Men with low-risk disease have multiple good options — active surveillance, surgery, or radiation all produce equivalent long-term outcomes.

The ten-year prostate cancer-specific mortality for low-risk disease managed appropriately is below 3 percent regardless of which approach is taken.

The most important thing for a low-risk patient to understand is that there is no clinical emergency. There is time to think, to get a second opinion, to understand the side effect profiles of each option, and to make a considered decision.

Men who feel pressured to act immediately after a low-risk diagnosis should seek a second specialist opinion before agreeing to treatment.

Intermediate risk — the group where decisions are most nuanced

Intermediate risk encompasses two meaningfully different subgroups — favourable and unfavourable — and the distinction matters for treatment decisions.

Favourable intermediate risk — Grade Group 2 (Gleason 3+4), PSA 10 to 20, or stage T2b — behaves more like low-risk disease. Selected patients with very favourable features may still be candidates for active surveillance.

Most will have surgery or radiation, typically without long-course hormone therapy.

Unfavourable intermediate risk — Grade Group 3 (Gleason 4+3), multiple intermediate-risk features, or cancer in more than 50 percent of cores — requires active treatment.

Radiation is typically combined with four to six months of hormone therapy. Surgery is appropriate for fit patients but the risk of needing adjuvant radiation afterwards is higher than in low-risk disease.

High risk and very high risk — where multidisciplinary planning is essential

High-risk disease — Gleason Grade Group 4 or 5 (Gleason 8 to 10), PSA above 20, or clinical stage T3 — requires aggressive, often multimodal treatment and formal multidisciplinary team review before any plan is finalised.

For high-risk locally advanced disease, the combination of external beam radiation and long-course hormone therapy (18 to 36 months) is the evidence-based standard.

Selected fit patients with high-risk localised disease may have surgery — typically with extended lymph node dissection — but adjuvant radiation and hormone therapy are frequently needed.

For any patient in the high-risk category, a hospital with a formal weekly prostate cancer tumour board — where urologists, radiation oncologists, and medical oncologists review the case together — is the right setting.

Medanta and Apollo Delhi both meet this standard. Tata Memorial in Mumbai provides the deepest specialist bench for the most complex high-risk presentations.

Getting Your Diagnostic Workup in India — What to Bring and What to Expect

---

Many international patients arrive in India with some investigations already done — a PSA result, perhaps an MRI, and possibly a biopsy. Others arrive with nothing except a vague sense that something is wrong and a recommendation to have a prostate check.

Understanding what to bring, what India can add, and what to expect from the diagnostic process helps enormously in planning your trip effectively.

What to bring from home

Bring every PSA result you have, with the date it was taken. Bring the written MRI report and, importantly, the actual imaging disc — not just the written summary.

Bring your biopsy pathology report in full, including the individual core results. Bring any staging scan reports — CT, bone scan, or PSMA PET-CT if done.

If you have had any previous prostate treatment — even a TURP for BPH — bring the operative report and the histology from the tissue removed. This information can be directly relevant to your current situation.

What India can add

India can do any investigation you have not had — PSA, mpMRI, biopsy, PSMA PET-CT, bone scan, CT staging, and comprehensive genomic profiling — faster and at a fraction of the cost compared to Western markets.

India can also provide a second pathological opinion on your biopsy tissue.

If your diagnosis was made in a country where uro-pathology expertise is limited, having the slides reviewed by a specialist pathologist at Tata Memorial or Medanta adds a valuable layer of quality assurance.

For patients who have been told they have prostate cancer but have never had a PSMA PET-CT, arriving in India to complete their staging workup before treatment decisions are finalised is a clinically sound strategy.

This is something GAF Healthcare co-ordinates regularly for international patients.

What to expect from the first consultation

The first consultation with an Indian uro-oncologist typically lasts 45 minutes to an hour. The specialist will review all your existing reports, ask about your symptoms, examine you, and then give you their assessment and recommendations.

At GAF Healthcare, every patient's first consultation is preceded by a pre-travel video call in which the specialist reviews your reports remotely and identifies any gaps in the workup before you travel.

This ensures you arrive in India with a clear plan rather than starting from scratch on the first day.

"My PSA was 18. My local doctor in Lagos referred me to a urologist who said I needed a biopsy immediately. He never mentioned an MRI first. I found GAF Healthcare online and sent my results. Their specialist said before any biopsy, I needed an mpMRI to see if there was a target. I came to India, had the MRI, and it showed a PI-RADS 5 lesion. The targeted biopsy came back Gleason 4+4. Without the MRI first, we might have missed the most important core."

— Mr. K. A., 61, Nigeria · Diagnostic workup at Apollo Delhi, 2025